I
Immatics N.V. (IMTX)
NCM – Real vaqt narxi. Valyuta: USD
11.39
-0.15 (-1.30%)
Yopilishda: May 12, 2026, 4:00 PM EDT
11.39
0.00 (0.00%)
Bozordan keyin: May 12, 2026, 5:42 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
11.39
-0.15 (-1.30%)
Yopilishda: May 12, 2026, 4:00 PM EDT
11.39
0.00 (0.00%)
Bozordan keyin: May 12, 2026, 5:42 PM EDT
Immatics N.V., klinik bosqichdagi bioptochilik kompaniyasi, AQShda saratonni davolash uchun potentsial T-hujayralarini yo'naltiruvchi immunoterapiyalarni tadqiq qilish va ishlab chiqishga qaratilgan. Kompaniya ikkita alohida davolash usuli, jumladan, adaptiv hujayra terapiyasi (ACT) va antiteloga o'xshash TCR Bispeksifiklar orqali qattiq o'smalarni davolashga qaratilgan maqsadli immunoterapiyalarni ishlab chiqmoqda. Uning mahsulotlar qatori Anzu-cel (IMA203), bir marta yuboriladigan PRAME hujayra terapiyasi, 2-bosqich sinovlarida; IMA203CD8, 1-bosqich klinik sinovlarda bo'lgan hujayra terapiyasi mahsuloti; IMA204, o'sma stromasini nishonga olgan, 1-bosqich klinik sinovlarda; va Moderna'ning PRAME hujayra terapiyasi kuchaytirgichi (mRNA-4203) bilan birgalikda Anzu-cel, 1-bosqich klinik sinovlarda. Kompaniya shuningdek, 1a bosqich klinik sinovlarda bo'lgan IMA401 va IMA402 ni o'z ichiga olgan TCR Bispeksifik mahsulotlarini ishlab chiqadi. Kompaniya bir nechta T-hujayrali va TCR asosidagi adaptiv hujayra terapiyalarini ishlab chiqish uchun MD Anderson Cancer Center bilan strategik hamkorlik shartnomasiga ega; bir nechta saraton turlarini nishonga olgan yangi adaptiv hujayra terapiyalarini ishlab chiqish uchun Celgene Corporation; va bir nechta saraton ko'rsatkichlarini nishonga olgan T-hujayralarini jalb qiluvchi bispeksifik immunoterapiyalarni ishlab chiqish uchun Genmab A/S. Immatics N.V. Germaniyaning Tyubingen shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Executive Director |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer |
| Mr. Edward A. Sturchio | General Counsel & Secretary |
| Mr. Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting & Accounting |
| Mr. Steffen Walter Ph.D. | Chief Operations Officer |
| Ms. Amie Krause | Chief People Officer |
| Ms. Lauren Schroeder | Vice President of Marketing |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-21 | 6-K | dp245406_6k.htm |
| 2026-04-17 | 6-K | dp245235_6k.htm |
| 2026-03-05 | 20-F | imtx-20251231.htm |
| 2026-01-12 | 6-K | dp239791_6k.htm |
| 2025-12-11 | 6-K | dp238568_6k.htm |
| 2025-12-08 | 6-K | dp238482_6k.htm |
| 2025-11-17 | 6-K | immatics_n.v._6-k_q325.htm |
| 2025-11-12 | 6-K | dp237236_6k.htm |
| 2025-10-27 | 6-K | dp236283_6k.htm |
| 2025-10-20 | 6-K | dp235990_6k.htm |